Skip to main content
. 2013 Oct 18;5(10):93. doi: 10.1186/gm499

Table 2.

Summary of the Coriell Personalized Medicine Collaborative drug-gene pharmacogenomics reports evaluated by the Pharmacogenomics Advisory Group

Drug and gene pair(s) Approval status Reason for rejection/deferral Highly actionable genetic results a
Warfarin and VKORC1 , CYP2C9 , CYP4F2 , or GGCX
All except GGCX approved
Insufficient clinical support for GGCX at time of submission evaluation
Low warfarin dose requirementb
Clopidogrel and CYP2C19
Approved
NA
Poor metabolizers
Tamoxifen and CYP2D6
Deferred
The data linking prognostic and predictive relevance of CYP2D6 variants to guide tamoxifen therapy for breast cancer was inconclusive. Vote has been deferred pending publication of anticipated clinical trials data
Vote deferred
Codeine and CYP2D6
Approved
NA
Ultra-rapid metabolizers
Metoprolol and CYP2D6
Rejected
Lack of clinical evidence, and given prescribing practices, the genetic results are unlikely to influence drug dose adjustment
NA
Thiopurines and TPMT
Approved
NA
Intermediate and poor metabolizers
PPIs and CYP2C19
Approved
NA
None
Diazepam and CYP2C19
Rejected
Evidence for clinical consequences is weak
NA
Statins and CYP3A4/CYP3A5 , SLCO1B1 , LDLR , or HMGCR
Simvastatin and SLCO1B1: approved, CYP3A4/CYP3A5: deferred. LDLR and HMGCR: rejected
LDLR and HMGCR: evidence for clinical utility is lacking
Simvastatin and SLCO1B1: genetic results associated with decreased hepatic drug uptake
Celecoxib and CYP2C9
Approved
NA
*3/*3
Fluorouracil and DPYD Rejected Combination of recent evidence for lower penetrance of reduced activity variants, and a lack of good alternative treatment reduces the clinical utility of the PGx information NA

Abbreviations: NA not applicable.

aGenetic results that warrant additional communication to participants who are at increased risk, and who have not viewed their risk report.

b‘Low dose’ is defined as a daily therapeutic dose of 0.5 to 2 mg based on the FDA drug label genotype guidelines table.